Associate, Bioqube Ventures As part of Bioqube’s investment team since 2016, Alex has been involved across the entire investment process for both portfolio investments and early stage venture creation as part of Bioqube’s dual investment model. Before the launch of BFFI, he supported the set-up and growth of multiple biotechs
Scientific Advisor, Advent Life Sciences Fraser is a neuropharmacologist with almost 30 years of drug discovery and early development experience across a range of therapeutic areas, including neurodegeneration, psychiatry, inflammation, gastrointestinal and dermatology. He has a wide C-suite experience in multiple biotech startups and held leadership roles at Shire, AstraZeneca,
Investment Director, Life Sciences, Bpifrance Investissements Since 2014 at Bpifrance Investissements, Benoit has been involved in a dozen investment deals and current board member positions include Alentis, Dynacure, Igyxos, Meiogenix and BrainEver. Prior to this, he gained experience in various biotech roles, co-discovered a vaccine candidate, and developed an antibody
Guillaune holds a Bachelor of Science, BsC. with a certificate in industrial bio-experimentations. He graduated from ESTBA Paris university. Guillaume started in academic research (INSERM) as a technician. He joined Tridek-One in 2019 and is specialized in preclinical models.
Laurence is a seasoned pharma/biotech professional with over 25 years of experience in transactions and R&D operations and general management. She has worked in VC funded biotech start-ups, mid-size private companies as well as large corporate organizations. Prior to joining Tridek-One, Laurence was COO and CBO of AMAL Therapeutics, a
Partner, AdBio Partners Clément Bertholet spent the first part of this carreer between life science and corporate finance. He graduated from Ecole Normale Supérieure (ENS Paris Saclay) with a major in Biology and Health and several experiences in Institut Curie and Cancer Research UK, before joining the Corps des Mines, a
Holger brings over 20 years of experience in Pharma, Biotech and Healthtech spanning multiple therapeutic areas and major elements of the value chain. He worked many years with Boehringer Ingelheim (BI) in different roles including Corporate VP Strategy and General Manager in European countries. Prior to joining BI, Holger was a